Cerenome, Inc. (CNSY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cerenome, Inc. (CNSY) has a cash flow conversion efficiency ratio of -0.522x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.24 Million) by net assets ($11.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review Cerenome, Inc. leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
Cerenome, Inc. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Cerenome, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Cerenome, Inc. market capitalisation for the company's overall valuation and market capitalisation.
Cerenome, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cerenome, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NBEST Prime VIII Inmuebles Socimi SA
MC:YINB8
|
0.011x |
|
Helios Towers Plc
LSE:HTWS
|
0.995x |
|
Vietnam Petroleum Transport JSC
VN:VIP
|
-0.030x |
|
Reyna Silver Corp
V:RSLV
|
-0.053x |
|
Woojin Plaimm
KO:049800
|
0.110x |
|
SGA Solutions Co.Ltd
KQ:184230
|
-0.097x |
|
FSBM Holdings Bhd
KLSE:9377
|
-0.082x |
|
Carelabs Co.Ltd
KQ:263700
|
-0.027x |
Annual Cash Flow Conversion Efficiency for Cerenome, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of Cerenome, Inc. from 2022 to 2025. View Cerenome, Inc. (CNSY) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.00 Million | $-20.77 Million | -5.199x | -540.83% |
| 2024-12-31 | $-8.95 Million | $-10.55 Million | 1.179x | -87.63% |
| 2023-12-31 | $-1.35 Million | $-12.85 Million | 9.533x | +573.66% |
| 2022-12-31 | $6.45 Million | $-12.97 Million | -2.013x | -- |
About Cerenome, Inc.
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cance… Read more